Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Taisho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT04873323
- Locations
- 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku, Japan
T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04795479
- Locations
- 🇺🇸
Single Site, Springfield, Missouri, United States
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 670
- Registration Number
- NCT04779242
- Locations
- 🇭🇺
Site 803, Debrecen, Hungary
🇧🇬Site 212, Vidin, Bulgaria
🇧🇬Site 206, Ruse, Bulgaria
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 72
- Registration Number
- NCT04688632
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Tempe, Arizona, United States
A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04660890
- Locations
- 🇺🇸
Clinical Trial Site, Tempe, Arizona, United States
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
- Conditions
- Interventions
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 50
- Registration Number
- NCT04563845
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT04560816
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 42
- Registration Number
- NCT04423744
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany
A Through QT/QTc Study of KW-6356
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT04342273
- Locations
- 🇯🇵
Medical Co. LTA Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵Medical Co. LTA Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, Japan
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- The University of Queensland
- Target Recruit Count
- 300
- Registration Number
- NCT04310930
- Locations
- 🇦🇺
St George Hospital, Kogarah, New South Wales, Australia
🇦🇺Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.